Related Experiment Video
Updated: Jan 20, 2026
Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Docking-based approach for identification of mutations that disrupt binding between Bcl-2 and Bax proteins: Inducing
Pawan Kumar Raghav1, Rajesh Kumar1,2, Vinod Kumar1,2
1Center for Computational Biology, Indraprastha Institute of Information Technology, New Delhi, India.
Background:
Inducing apoptosis in cancer cells is an important step for the successful treatment of cancer patients. Bcl-2 is an antiapoptotic protein which determines apoptosis by interacting with proapoptotic members of the Bcl-2 family. Exome sequencing has identified Bcl-2 and Bax missense mutations in more than 40 cancer types. However, a little information is available about the functional impact of each Bcl-2 and Bax mutation on the pathogenesis of cancer.
Methods:
The mutational data from cancer tissues and cell lines were retrieved from the cBioPortal web resource. The 13 mutated Bcl-2 and wild-type Bax complexes with experimentally verified binding were identified from previous studies wherein, binding for all complexes was reportedly disrupted except one. Several protein-protein docking methods such as ClusPro, HDOCK, PatchDock, FireDock, InterEVDock2 and several mutation prediction methods such as PolyPhen-2, SIFT, and OncoKB have been used to predict the effect of mutation to disrupt the binding between Bcl-2 and Bax. The result obtained was compared with the known experimental data.
Results:
The protein-protein docking method, ClusPro, employed in the present study confirmed that the binding affinity of 11 out of 13 complexes decreases. Similarly, binding affinity computed for all the 10 wild-type Bcl-2 and mutated Bax complexes agreed with experimentally verified results.
Conclusion:
Several methods like PolyPhen-2, SIFT, and OncoKB have been developed to predict cancer-associated or deleterious mutations, but no method is available to predict apoptosis-inducing mutations. Thus, in this study, we have examined the mutations in Bcl-2 and Bax proteins that disrupt their binding, which is crucial for inducing apoptosis to eradicate cancer. This study suggests that protein-protein docking methods can play a significant role in the identification of hotspot mutations in Bcl-2 or Bax that can disrupt their binding with wild-type partner to induce apoptosis in cancer cells.
Insights
Mutations in Bcl-2 and Bax proteins can disrupt their binding, potentially inducing cancer cell apoptosis. Protein-protein docking methods effectively identify these cancer-driving mutations, aiding in targeted cancer therapy development.
Area of Science:
- Oncology
- Molecular Biology
- Biophysics
Background:
- Inducing apoptosis is crucial for effective cancer treatment.
- Bcl-2, an anti-apoptotic protein, interacts with pro-apoptotic proteins.
- Missense mutations in Bcl-2 and Bax are found in over 40 cancer types, but their functional impact is poorly understood.
Purpose of the Study:
- To investigate the functional impact of Bcl-2 and Bax mutations on their binding affinity.
- To identify mutations that disrupt Bcl-2 and Bax interaction, potentially inducing apoptosis.
- To evaluate the utility of protein-protein docking methods in predicting these functionally significant mutations.
Main Methods:
- Retrieved mutational data from cBioPortal.
- Utilized protein-protein docking (ClusPro, HDOCK, etc.) and mutation prediction tools (PolyPhen-2, SIFT, OncoKB).
- Compared computational predictions with experimentally verified binding data for 13 Bcl-2/Bax complexes.
Main Results:
- Protein-protein docking confirmed decreased binding affinity in 11 out of 13 mutated Bcl-2/wild-type Bax complexes.
- Computational predictions for wild-type Bcl-2/mutated Bax complexes aligned with experimental findings.
- Identified specific mutations that disrupt Bcl-2 and Bax binding.
Conclusions:
- Protein-protein docking methods are valuable for identifying cancer-associated mutations in Bcl-2 and Bax that disrupt binding.
- Disruption of Bcl-2/Bax binding is a key mechanism for inducing apoptosis in cancer cells.
- This approach can aid in developing targeted therapies by identifying mutations that promote cancer cell death.
Related Concept Videos
08:35Examining BCL-2 Family Function with Large Unilamellar Vesicles
14:28Peptide-based Identification of Functional Motifs and their Binding Partners
06:03Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
10:23Covalent Binding of BMP-2 on Surfaces Using a Self-assembled Monolayer Approach
10:52Sample Preparation for Mass Spectrometry-based Identification of RNA-binding Regions